Skip to content
Screener

GoodRx Holdings, Inc. GDRX Pharma Direct revenue — Revenue

Other product segments

Pharma manufacturer solutions revenue
$151.38M
Prescription transactions revenue
$106.39M-25.6%
Subscription revenue
$28.51M+39.3%
Other revenue
$3.88M-15.0%

Similar metrics at other companies

Paysign logo
PAYSPharma Industry — Revenue
$14.65M+88.9%
Grid Dynamics Holdings, Inc. logo
GDYNHealthcare and Pharma — Revenue
$2.15M-10.4%
Worthington Steel logo
WSDirect — Revenue
$743M+13.6%
Weis Markets logo
WMKPharmacy — Revenue
$167.19M+5.4%
Kforce logo
KFRCDirect Hire revenue — Revenue
$7.5M+27.0%
Icahn Enterprises logo
IEPPharma — Revenue
$17M-50.0%

Other financials

Income statement

See full
Revenue$200.4M-1.3%
Gross profit$179.4M-5.4%
Operating income$23.6M-11.9%
Net income$8.5M-33.5%
EPS (diluted)$0.02-50.0%

Balance sheet

See full
Cash & equivalents$296.1M+5.3%
Total debt$539.0M-1.6%
Total equity$647.6M+0.7%
Total assets$2.3B+77.7%

Cash flow

See full
Operating cash flow$80.8M+63.0%
CapEx$362.0K-7.2%
Free cash flow$80.5M+63.6%

Valuation

See full
Market cap$1.27B-18.1%
Enterprise value$1.51B-16.8%
P/E78.1×+33.3×
P/S1.6×-0.3×

Profitability

See full
Gross margin90.8%-2.8pp
Operating margin9.5%-1.6pp
Net margin2.1%-2.3pp
FCF margin25.1%+1.4pp

Returns & leverage

See full
Return on equity2.5%-2.8pp
Debt / equity0.8×0.0×
Current ratio1.4×-2.8×

Where this comes from

Reported directly by GoodRx Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: GoodRx Holdings, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001809519-26-000152
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Prescription transactions revenue$106,390$143,064$220,082$291,987
Subscription revenue28,51420,46352,90741,480
Pharma Direct revenue61,62834,981113,85863,629
Other revenue3,8794,5627,5708,944
Total revenue$200,411$203,070$394,417$406,040

Item 1. Financial Statements

FAQ

What is GoodRx Holdings, Inc.'s pharma direct revenue — revenue?
GoodRx Holdings, Inc. (GDRX) reported pharma direct revenue — revenue of $61.63M in Q2 2026.
How has GoodRx Holdings, Inc.'s pharma direct revenue — revenue changed year-over-year?
GoodRx Holdings, Inc.'s pharma direct revenue — revenue increased by 76.2% year-over-year, from $34.98M to $61.63M.
What is the long-term trend for GoodRx Holdings, Inc.'s pharma direct revenue — revenue?
Over 3 years (2021 to 2024), GoodRx Holdings, Inc.'s pharma direct revenue — revenue has grown at a 13.5% compound annual growth rate (CAGR), from $73.35M to $107.24M.
What does pharma direct revenue — revenue mean?
This metric represents revenue generated from pharmaceutical manufacturers through direct marketing and promotional solutions on the platform. It reflects the company's ability to monetize its user base by connecting drug makers with consumers and healthcare providers for brand awareness and patient access programs. This revenue stream is a key indicator of the platform's utility as a digital advertising and engagement channel for the life sciences industry.

Ask your AI about GoodRx Holdings, Inc.'s pharma direct revenue — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude